Clinical Trial Update: A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 dose-escalation and expansion study of intratumoral SAR441000 as monotherapy and in combination with cemiplimab in patients with advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• Cemiplimab (cemiplimab)
• SAR441000

Snippet

Sponsor: Sanofi | Conditions: Metastatic Neoplasm | Phase 1 | Status: TERMINATED